Page 243 - Drug Class Review
P. 243
Drug Effectiveness Review Project
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes
72.7; 72.9; 75.4 placebo galantamine 18; 24; 36 mg/d 74.2 59 56; 59; 57 NR NR 18.7 18.8, 18.2, 18.8 26.9 26.0, 26.7, 25.7 Primary Outcome Measures: ADAS-Cog Secondary Outcome Measures: CGIC; PDS-1 (quality of life measure) Timing of assessments: Baseline and weeks 6 and 12 Health Outcome Measures: No significant differences in PDS-1 score for any dose of GAL compared to placebo (ITT) Intermediate Outcome Measures: GAL 24 mg/d produced greater improvement in ADAS-Cog change compared to placebo (P = 0.01); mean change from baseline for GAL
• • •
Final Report Update 1 Authors: Wilkinson et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Baseline MMSE • Baseline ADAS-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
